Eradication Strategies for Chronic Hepatitis B Infection.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 27190322.
- Also identified by DOI 10.1093/cid/ciw044 and PMC identifier 4889898.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Chronic hepatitis B infection affects >300 million people worldwide and is a leading cause of liver failure and cancer. Current approaches to treatment for chronic hepatitis B involve suppression of hepatitis B virus (HBV) DNA with the use of nucleoside analogues. Chronic suppressive therapy rarely results in a "functional cure" or absence of detectable HBV DNA in plasma and loss of detectable hepatitis B surface antigen after cessation of therapy. The major obstacles to achieving a functional cure are the presence of covalently closed circular DNA and ineffective/exhaustive immune system. This review focuses on novel approaches to target viral life cycle and host immunity to achieve a functional cure.
Medical subject headings
- Antiviral Agents
- Hepatitis B virus
- Hepatitis B, Chronic